PhaseV Announces New ClinOps AI Platform: Transforming Clinical Trial Operations with Precision-Guided Site Selection

Powered by Causal AI and Real-Time Patient-Level Data and Analytics, the ClinOps Platform Enables Faster and Smarter Decision Making Across Trial Lifecycles

BOSTON, July 1, 2025 /PRNewswire/ -- PhaseV, a leader in AI/ML-driven clinical development, today announced the launch of the ClinOps platform, a next-generation solution designed to modernize clinical trial operations through precision-guided site selection and dynamic performance monitoring. Built on causal machine learning and real-world patient-level data, the ClinOps platform enables study teams to move beyond historical benchmarks and make operational decisions with greater speed and accuracy.

"Our ClinOps platform provides a new standard for how trials are planned and executed," said Raviv Pryluk, PhD, CEO and Co-founder of PhaseV. "We go much deeper than traditional feasibility and site selection tools, providing real-time visibility into the factors driving trial success and allowing trial teams to interact with their data in unprecedented ways. This provides execution teams with a new level of confidence as they make decisions that drive better outcomes."

The ClinOps platform is the latest addition to PhaseV's vertical AI solution, which is used by over 30 leading pharma, biotech sponsors, and CROs across more than 20 therapeutic areas. Its launch coincides with the appointment of Melanie Ivarsson OBE, PhD, former Senior Vice President and Chief Development Officer at Moderna, to PhaseV's advisory board. Her extensive pharmaceutical expertise, including leading the development of one of the world's first COVID-19 vaccinations, will be instrumental in driving the platform's technological development and market adoption. 

"By integrating causal inference, patient-level analytics, and intuitive operational tooling, the ClinOps platform empowers teams to improve equity, reduce inefficiencies, and bring greater precision to clinical trial execution," said Dr. Ivarsson. "This combination is incredibly powerful and will positively transform clinical development. I am excited to join PhaseV and contribute to this important step forward for the industry."

Precision-Guided Site Selection

Conventional site selection tools typically rely on retrospective averages and static performance metrics. PhaseV takes a different approach, using causal machine learning to model the factors that drive site variability and patient heterogeneity. The ClinOps platform takes into account patient-level covariates, including age, BMI, ethnicity, comorbidities, genomics, and prior treatments, aligning with the mechanism of action (MoA) of the therapeutic asset and eligibility criteria. In this way, the platform provides data-driven recommendations for optimal trial sites, ensuring a higher probability of success, faster recruitment rates, and real-world patient diversity.

Instead of treating clinical trial feasibility as a one-time task, the ClinOps platform allows users to interactively explore global site recommendations based on specific trial parameters, therapeutic context, and target populations. The result is a more nuanced and adaptive process that improves participant representation, reduces enrollment risk, and minimizes exposure to low-performing or congested sites.

Continuous Oversight with Real-Time Performance Analytics

Once a trial is underway, the ClinOps platform continues to play a key role through real-time site and trial performance monitoring. Operational teams can track shifting enrollment dynamics, assess site-level performance and detect emerging risks, all from a centralized, data-rich dashboard.

Predictive models uncover early indicators of site success or underperformance, while intelligent alerts help teams respond quickly to deviations or bottlenecks. With trend analysis across cohorts, timepoints, and geographies, study teams gain the insights needed to stay on track and act decisively.

Optimized Execution Across the Trial Lifecycle

Designed to support decision-making from protocol design to last patient out, the ClinOps platform enhances operational strategy at every phase of the trial lifecycle:

• Pre-launch: Optimizes eligibility criteria and trial design using modeled patient populations
• Site selection: Identifies high-fit sites based on performance likelihood and population match
• Post-activation: Monitors site behavior in real time and adapts plans proactively

About PhaseV

PhaseV is developing advanced AI/ML solutions to optimize clinical development. Biopharma sponsors and CROs are leveraging PhaseV's platform to rapidly design and execute adaptive, Bayesian and fixed clinical trials, analyze data to uncover heterogeneous treatment effects, stratify patients, and inform future R&D and portfolio decisions. PhaseV's platform has reduced trial costs by 50%, decreased enrollment size and trial duration by 40%, and increased the probability of trial success by over 30%. To date, the company has delivered results for more than 30 leading pharma/biotech sponsors and CROs spanning multiple therapeutic areas, including neurology, oncology, immunology, GI, rare diseases, and others.

Learn more at www.PhaseVTrials.com and follow us on LinkedIn.

Video - https://www.youtube.com/watch?v=xgMP8DEZgKw
Logo - https://mma.prnewswire.com/media/2722715/PhaseV_Logo.jpg

Media Contact: 
Ellie Hanson
FINN Partners for PhaseV
ellie.hanson@finnpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/phasev-announces-new-clinops-ai-platform-transforming-clinical-trial-operations-with-precision-guided-site-selection-302495530.html

SOURCE PhaseV